Literature DB >> 12660812

MAP kinase activation by interleukin-9 in lymphoid and mast cell lines.

Jean-Baptiste Demoulin1, Jamila Louahed, Laure Dumoutier, Monique Stevens, Jean-Christophe Renauld.   

Abstract

Interleukin-9 (IL-9) stimulates the proliferation of mast cells and lymphocytes. In the present study, we showed that IL-9 induced a transient phosphorylation of MEK, ERK2 and p90/RSK in murine lymphoid and mast cell lines. ERK2 in vitro kinase activity was also increased upon IL-9 stimulation. Similar results were obtained with IL-4, which had not been previously reported to activate these kinases in hematopoietic cells. Analysis of IL-9 receptor mutants showed that activation of the pathway was correlated with proliferation and with phosphorylation of the adaptor protein SHC, but not IRS2 or GAB2. The MEK inhibitor PD98059 reduced the mitogenic response to IL-4 and IL-9. In addition, expression of a dominant-negative RAS variant blocked ERK phosphorylation and significantly decreased Ba/F3 cell growth in the presence of IL-9, but did not affect expression of pim-1, a STAT target gene. In summary, these results indicate that IL-9 can transiently activate the mitogen-activated protein kinase pathway, which contributes to growth stimulation of hematopoietic cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660812     DOI: 10.1038/sj.onc.1206253

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Cloning and functional testing of rhesus macaque (Macaca mulatta) IL-9 and IL-33.

Authors:  Sanghita Sarkar; Ann J Hessell; Nancy L Haigwood; James J Kobie
Journal:  J Med Primatol       Date:  2020-02-04       Impact factor: 0.667

Review 2.  Interleukin-9 and T helper type 9 cells in rheumatic diseases.

Authors:  F Ciccia; G Guggino; A Ferrante; P Cipriani; R Giacomelli; G Triolo
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

Review 3.  A brief history of IL-9.

Authors:  Ritobrata Goswami; Mark H Kaplan
Journal:  J Immunol       Date:  2011-03-15       Impact factor: 5.422

4.  Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.

Authors:  Sandrine Medves; Laura A Noël; Carmen P Montano-Almendras; Roxana I Albu; Hélène Schoemans; Stefan N Constantinescu; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

5.  From bench to bedside: Therapeutic potential of interleukin-9 in the treatment of asthma.

Authors:  Fang Gong; Yu-Hong Pan; Xuan Huang; Hua-Yan Zhu; Dong-Lin Jiang
Journal:  Exp Ther Med       Date:  2017-01-04       Impact factor: 2.447

6.  PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.

Authors:  F A Arts; D Chand; C Pecquet; A I Velghe; S Constantinescu; B Hallberg; J-B Demoulin
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

Review 7.  An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis.

Authors:  Sushmita Chakraborty; Katharina F Kubatzky; Dipendra Kumar Mitra
Journal:  Int J Mol Sci       Date:  2019-04-29       Impact factor: 5.923

8.  A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.

Authors:  Dinel Pond; Florence A Arts; Nancy J Mendelsohn; Jean-Baptiste Demoulin; Gunter Scharer; Yoav Messinger
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

9.  IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity.

Authors:  Elizabeth E Forbes; Katherine Groschwitz; J Pablo Abonia; Eric B Brandt; Elizabeth Cohen; Carine Blanchard; Richard Ahrens; Luqman Seidu; Andrew McKenzie; Richard Strait; Fred D Finkelman; Paul S Foster; Klaus I Matthaei; Marc E Rothenberg; Simon P Hogan
Journal:  J Exp Med       Date:  2008-03-31       Impact factor: 14.307

10.  Role of IL-9 and STATs in hematological malignancies (Review).

Authors:  Na Chen; Xin Wang
Journal:  Oncol Lett       Date:  2013-12-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.